Predicta Biosciences
Boston
About Predicta Biosciences
Predicta Biosciences delivers molecular diagnostics, artificial intelligence tools, and immunotherapeutic discovery services for hematological diseases. It operates a platform that uses whole-genome sequencing of bone marrow biopsies and circulating tumor cells to replace conventional assays and support high-resolution disease monitoring. The company complements genomic data with multiomic immune profiling to inform personalized therapy decisions. Its AI/ML engine mines a growing patient database to uncover novel therapeutic targets. Its focus includes diagnostics across patient disease progression and internal immunotherapy development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $28.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2025)
- Website: predictabiosciences.com
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Diagnostics, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/predicta-biosciences-29874 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.